Earnings Call Summary | Biote(BTMD.US) Q2 2024 Earnings Conference
Earnings Call Summary | Biote(BTMD.US) Q2 2024 Earnings Conference
The following is a summary of the Biote Corp. (BTMD) Q2 2024 Earnings Call Transcript:
以下是Biote Corp. (BTMD) 2024年Q2業績會議通話記錄摘要:
Financial Performance:
金融業績:
Total Q2 2024 revenue was $49.2 million, stable year-over-year, with a notable increase in procedure revenue by 7.8%.
Gross profit margin for the quarter improved to 68.9%, a 100 basis point improvement from the previous year, primarily due to better product mix and cost management.
Adjusted EBITDA for the quarter was $12.7 million, down 12.4% from the previous year, reflecting strategic investments.
Operating income for Q2 was $6.2 million, with a slight decrease from the previous year's $7.7 million.
2024年Q2總營業收入爲4920萬美元,同比持平,其中手術收入增長了7.8%。
本季度毛利潤率提高到68.9%,較上年有100個點子的改善,主要是由於產品組合和成本管理方面的改進。
本季度調整後的EBITDA爲1270萬美元,較上年下降了12.4%,反映出戰略性投資。
Q2的營業收入爲620萬美元,與去年的770萬美元相比略有下降。
Business Progress:
業務進展:
The company is expanding its BioteRx platform and introducing major enhancements to the Biote method, affirming its commitment to providing comprehensive, evidence-based therapeutic wellness solutions.
Successfully integrated Asteria Health, enhancing manufacturing efficiency and expanding the product range, including new offerings in body composition, sexual wellness, and thyroid conditions.
Achieved a settlement in litigation with two large shareholders, coupled with significant share repurchases, effectively enhancing long-term shareholder value.
公司正在擴展其BioteRx平台,並對Biote方法進行重大改進,肯定了其提供全面、以證據爲基礎的治療健康方案的承諾。
成功整合Asteria Health,提高了製造效率並拓展了產品範圍,包括身體構成、性健康和甲狀腺疾病等新產品。
與兩位大股東達成和解,並大量回購股份,有效增強了長期股東價值。
Opportunities:
機會:
Continued rollout of BioteRx across the network, providing a competitive edge in the hormone and therapeutic wellness market through a wide range of products and enhanced practitioner support.
Prospects for growth in nutraceutical sales in the latter half of the year following a strategic shift in distribution and product management.
繼續在網絡中推廣BioteRx,通過廣泛的產品和增強的從業者支持,爲激素和治療健康市場提供競爭優勢。
在轉變了分銷和產品管理策略之後,後半年保健食品銷售前景看好。
Risks:
風險:
Potential challenges in the growing therapeutic wellness market, such as regulatory hurdles and the need for continuous product and service innovation to maintain a competitive edge.
在增長的治療健康市場中可能面臨的挑戰,例如監管障礙和需要持續的產品和服務創新以保持競爭優勢。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:如需更全面的詳情,請參閱投資人關係網站。本文僅供投資者參考,不作任何指引或建議。
譯文內容由第三人軟體翻譯。